| Multiple Sclerosis
Ampyra vs Tysabri
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis.Deep comparison between: Ampyra vs Tysabri with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTysabri has a higher rate of injection site reactions vs Ampyra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tysabri but not Ampyra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ampyra
Tysabri
At A Glance
Oral
Twice daily
Potassium channel blocker
IV infusion
Every 4 weeks
alpha4-integrin antagonist
Indications
- Multiple Sclerosis
- Multiple Sclerosis
- Crohn Disease
Dosing
Multiple Sclerosis 10 mg tablet twice daily approximately 12 hours apart; do not exceed 10 mg twice daily; swallow tablets whole; may be taken with or without food.
Multiple Sclerosis 300 mg IV infusion over one hour every four weeks.
Crohn Disease 300 mg IV infusion over one hour every four weeks; discontinue if no therapeutic benefit by 12 weeks of induction therapy or if concomitant corticosteroids cannot be tapered within six months of starting therapy.
Contraindications
- History of seizure
- Moderate or severe renal impairment (CrCl <=50 mL/min)
- History of hypersensitivity to AMPYRA or 4-aminopyridine, including anaphylaxis
- Progressive multifocal leukoencephalopathy (PML), current or historical
- Previous hypersensitivity reaction to TYSABRI, ranging from urticaria to anaphylaxis
Adverse Reactions
Most common (>=2%) Urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, pharyngolaryngeal pain
Serious Seizures, anaphylaxis
Postmarketing Vomiting, vertigo
Most common (>=10%) Headache, fatigue (MS and CD); arthralgia, urinary tract infection, lower respiratory tract infection, gastroenteritis, vaginitis, depression, pain in extremity, abdominal discomfort, diarrhea, rash (MS); upper respiratory tract infection, nausea (CD).
Serious Progressive multifocal leukoencephalopathy (PML), herpes infections, hepatotoxicity, hypersensitivity and antibody formation, immunosuppression and infections, hematological abnormalities.
Postmarketing Hemolytic anemia, thrombocytopenia (including immune thrombocytopenic purpura).
Pharmacology
Dalfampridine is a broad spectrum potassium channel blocker that increases conduction of action potentials in demyelinated axons through inhibition of potassium channels; the mechanism by which it improves walking in MS has not been fully elucidated.
Alpha4-integrin antagonist; recombinant humanized IgG4 monoclonal antibody that binds to the alpha4-subunit of alpha4beta1 and alpha4beta7 integrins on leukocytes, blocking their adhesion to VCAM-1 and MAdCAM-1 and inhibiting transmigration into inflamed parenchymal tissue in multiple sclerosis and Crohn's disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ampyra
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Tysabri
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ampyra
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Tysabri
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ampyra
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Tysabri
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AmpyraView full Ampyra profile
TysabriView full Tysabri profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.